Pulmonary Metastases Clinical Trial
Official title:
Thoracoscopic Ultrasonography Versus Manual Lung Palpation by Thoracotomy for the Identification of Lung Nodules During Pulmonary Metastasectomy. A Prospective Blinded Cross-over Trial.
Experience drawn from many scientific articles showed that many patients who develop a
limited pattern of pulmonary metastases after treatment of a primary tumor may benefit from
surgical resection of the lung deposits. Pulmonary metastasectomy with curative intent is
widely performed with the aim of prolonging life and, in some cases, being curative. Usually
the surgical strategy is defined based on analysis of radiological investigations, performed
during a follow-up program after resection of a tumor. However, many studies showed that the
actual sensitivity of this examinations, namely computed tomography (CT) and
positron-emission tomography (PET) is far from being 100% and finding further unexpected
nodules at operation with lung manual palpation is not uncommon. Many surgeons perform
pulmonary metastasectomy with a minimally invasive approach, in view of a less morbid and
more cosmetic approach, but lung palpation is considerably hampered and surgical radicality
might be impaired. With this study the investigators want to assess the ability of lung
ultrasonography performed via a key-hole access (thoracoscopy, VATS) in detecting lung
nodules compared with the standard practice represented by open thoracotomy, that is a wider
incision that allows manual exploration of the organ. Therefore, every patient enrolled will
undergo a double phase surgical approach: a first phase by thoracoscopy where a thorough lung
ultrasonography will be performed and number and position of lung nodules will be annotated,
and a second phase by open thoracotomy where lung is palpated and suspicious nodules will be
removed. The incisions used for the first phase will be extended for the second, rendering
any other procedure for the execution of lung ultrasonography unnecessary.
Should this study demonstrate a non-inferiority of lung ultrasonography in detecting lung
nodules compared with manual palpation of the lung, patients should be offered a less
invasive approach for treatment of their condition with no concerns regarding a potential
lower therapeutic effect.
Pulmonary metastasectomy is a surgical practice that poses many aspects of debate: standard
approach has historically been represented by open thoracotomy, but video-assisted thoracic
surgery (VATS) became an appealing alternative due to the lower surgical impact on the
patient. Some authors blame the minimally invasive approach for pulmonary metastasectomy as
less effective from an oncologic point of view since lung palpation is hampered, leading to
reduced ability to identify unexpected nodules and potential impairment of surgical
radicality.
Indeed, several papers demonstrated a suboptimal sensitivity of computed tomography (CT) and
positron-emission tomography (PET) in detecting lung metastases and discover of further
unexpected nodules at thoracotomy are not an uncommon eventuality.
A few authors demonstrated the utility of intraoperative lung ultrasound performed through a
VATS approach (VATS-US) in identifying lung nodules. However, the real effectiveness of this
technique has never been prospectively compared with the current gold standard represented by
open thoracotomy and lung manual exploration. Aim of our study is to assess the
non-inferiority of VATS-US compared with manual palpation to identify lung nodules during
pulmonary metastasectomy.
The study design is a monocentric non-inferiority diagnostic crossover trial, based on the
execution of intraoperative lung ultrasound (VATS-US) in patients undergoing pulmonary
metastasectomy with radical intent. Aim of the study is to assess the non-inferiority of the
ultrasonographic investigation on the lung parenchyma performed via a thoracoscopic approach
in identifying lung nodules compared with manual organ palpation by thoracotomy.
Study design After general anesthesia administration patients will be intubated with a double
lumen tube and positioned in a standard lateral decubitus. Thereby the target lung will be
excluded from ventilation and deflated. After creation of 2-3 thoracoscopic ports the lung is
explored under thoracoscopic vision with a laparoscopic ultrasound probe (Esaote LP323,
Esaote, Genova, Italy) by a surgeon with experience on the use of lung ultrasound. Data
regarding number, size, depth and lobar localization of nodules are registered on a data
collection paper. The surgeon who performed the investigation therefore leaves the operative
room and another surgeon, blind to the previous phase findings, performs an anterolateral
thoracotomy and an accurate palpation of the lung. Suspicious nodules are therefore resected
and sent for histology. Data on number and localization of excised nodules are registered on
a separate collection paper. Results from both phases are then compared and matched with
histology report.
Thoracotomy will be performed extending the length of the utility port. The others 1-2 hole
are eventually used for insertion of chest drainage tubes, that in our institution are
routinely positioned following any intervention within the pleural space. Consequently, no
adjunctive incision will be performed for the execution of VATS-US compared with a standard
thoracotomy approach. Only after nodules resection the two surgeons will compare their
findings in order to make sure that any nodule identified at VATS-US but not at thoracotomy
has not been omitted. The execution of the ultrasonographic investigation will require an
appropriate lung deflation. Therefore, in some cases air aspiration from the target lung with
a small catheter inserted through the endobronchial tube will be required, as previously
described in other studies.
In order to guarantee patients' safety, they will never be left unattended during all phases
of the intervention, and execution of any required urgent procedure for rare intraoperative
complications will never be delayed, including those that may interfere with the execution of
the ultrasonographic exam. It has been calculated that operative time will be extended of
about 20-30 minutes to allow the execution of VATS-US.
No extra procedure or drugs administration will be required for the study. Only nodules that
will be considered suspicious by the second surgeon during the thoracotomic phase or after
discussion between the two operators will be excised, as expected in the standard practice.
The investigators will collect data regarding patients' features (age, biometric
measurements, preoperative lung function tests data, lung comorbidities), preoperative CT
scan findings (number, size and localization of lung nodules), ultrasonographic findings
(number, size, depth, localization and shape of lung nodules), number and localization of
nodules excised at thoracotomy, histology report data (histological nature, size, depth of
lung nodules), time of surgery and of VATS-US, incidence of post-operative adverse events.
Sample size and statistical analysis Sensitivity and specificity of VATS-US will be
calculated compared with manual palpation. The inter-rater agreement will be measured by
calculating Cohen's kappa coefficient. Continuous data will be summarized as mean and
standard deviation or median and twenty-fifth to seventy-fifth percentiles in case of
non-normal distributions. Normality will be assessed by using Shapiro-Wilk test. Categorical
variables will be reported as counts and percentages. Comparisons will be carried out using
paired t-test, Wilcoxon signed ranks test and McNemar test where appropriate.
STATA software (release 14 StataCorp LP, College Station, TX, USA) will be utilized for
analysis.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT00280189 -
Study of Outcomes of Radiofrequency Ablation of Lung Tumors
|
||
Recruiting |
NCT01216371 -
Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)
|
Phase 2 | |
Completed |
NCT05101655 -
Construction of Microfluidic Exosome Chip for Diagnosis of Lung Metastasis of Osteosarcoma
|
||
Recruiting |
NCT01105182 -
Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors
|
N/A | |
Completed |
NCT00690703 -
Radiofrequency Ablation of Pulmonary Tumors Response Evaluation
|
Phase 2 | |
Withdrawn |
NCT03297463 -
Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT02811523 -
In Vivo Lung Perfusion for Pulmonary Metastases of Sarcoma
|
Phase 1 | |
Recruiting |
NCT06265350 -
Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases
|
N/A | |
Completed |
NCT01106261 -
A Randomised Trial of Pulmonary Metastasectomy in Colorectal Cancer
|
N/A | |
Withdrawn |
NCT04648826 -
Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03742193 -
Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy
|
Phase 2 |